StemCell Therapy

Medicine has always been personalized what has changed are the tools available that allow us to provide better care for you. The Institute for Personalized Medicine is Penn State Health's commitment to advancing health care for our community through the use of modern technology and more effective tools.

In the past, doctors based treatments on research that studied broad groups of people, finding what is most likely to help a majority of patients. While this approach has been successful, its not always efficient since each of us is different. Our genetics and our biology are unique to us, so treatments that work best for one person may not work best for another.

Personalized medicine is the use of individual characteristics to tailor treatments to the person. For example, one person may respond to a medicine differently than another because of their genetics. By knowing what that genetic difference is, doctors can look for the same in future patients and prescribe medication accordingly helping to recover faster.

Penn State Institute for Personalized Medicine gives scientists the tools to develop research studies seeking this information, and future therapies for patients.

Continue reading here:
Personalized Medicine | Penn State Health

DUBLIN, Nov. 11, 2020 /PRNewswire/ -- The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Story continues

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2023.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Finally the bibliography contains over 750 selected publications cited in the report. The report is supplemented by 88 tables and 50 figures.

Key Topics Covered:

Part I: Scientific Basis & Technologies

Executive Summary

1. Basic Aspects

2. Molecular Diagnostics in Personalized Medicine

3. Pharmacogenetics

4. Pharmacogenomics

5. Role of Pharmacoproteomics

6. Role of Metabolomics in Personalized Medicine

7. Personalized Biological Therapies

8. Personalized complementary & Alternative Therapies

9. Personalized Medicine in Major Therapeutic Areas

10. Personalized Therapy of Cancer

11. Development of Personalized Medicine

12. Ethical, Legal and Regulatory Aspects of Personalized Medicine

Part II: Markets & Companies

13. Markets for Personalized Medicine

14. Companies Involved in Developing Personalized Medicine

15. References

For more information about this report visit https://www.researchandmarkets.com/r/ty8o34

Source: Jain PharmaBiotech

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-2029-301170831.html

SOURCE Research and Markets

Read more here:
Personalized Medicine Market, 2029

LONDON--(BUSINESS WIRE)--The global biochip market size is poised to grow by USD 19.71 billion during 2020-2024, progressing at a CAGR of 22% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

Personalized medicines growing popularity and demand is expected to drive the growth of the Biochip market. The medicines are personalized as per the patients needs which suits the individual characteristics of the person is a multi-faceted approach. This improves the ability to diagnose and effectively treat the disease as this technique facilitates early diagnosis. These biochips play an important part in the development of these medicines, as it improves the ability to diagnose and effectively treat the disease. It is also expected that during the forecast period the growing incidences of genetic and terminal diseases will influence the demand for personalized medicine for targeted drug development. This will increase the demand for biochips which will result in the growth of this industry.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Report Highlights:

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Rising Use of Biochips in Safety Detection of Agriculture Products will be a Key Market Trend

The rising use of biochip technology in the agriculture industry is turning out to be one of the major trends in the biochip industry. Biochip helps in the detection of pathogenic microorganisms, biological toxins, pesticide residues, and antibiotics. Microchips help in providing early warning to agricultural products' monitoring with a rapid response system and, thus, enhance the agricultural products' safety detection system. Therefore, significantly helping the agriculture industry from the loss it faces every year.

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Biochip Market 2020-2024: Key Highlights

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Biochip Market | Increased Popularity of Personalized Medicine to Boost the Market Growth | Technavio - Business Wire

THE HAGUE, Netherlands, Dec. 5, 2020 /PRNewswire/ --The HARMONY Alliance announces new analyses demonstrating how Big Data can facilitate personalized medicine in patients with blood cancers, also known as Hematologic Malignancies. Using data from around 12,000 AML and MM patients comprised in the HARMONY Big Data Platform, the researchersobtained fascinating insights into the molecular basis of Acute Myeloid Leukemia (AML) and developed an improved risk stratification model for Multiple Myeloma (MM). These results are presented during the 62nd American Society of Hematology Annual Meeting.

Harmony Alliance Provides Novel Insights into Acute Myeloid Leukemia Based on a Pan-European NGS Data Collection (abstract 1077- Bullinger et al)

Lars Bullinger, HARMONY Partner Charit Berlin, Germany:

"We have analyzed genomic data of 4,986 patients with AML. We could confirm the co-occurrence of certain mutations. In addition, we obtained insight into which mutations occur first and which later in the disease process. We have also investigated the association of mutation patterns with clinical outcomes such as remission, relapse, and survival. For instance, many patients with high-risk mutation patterns benefit only little from an allogeneic stem cell transplantation (alloSCT), but we found specific high-risk genotype combinations that predict a much larger survival benefit."

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7,077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (abstract 1329- D'Agostino et al)

Mattia D'Agostino, HARMONY Partner University of Turin, Italy:

"Clinical outcomes for patients with MM vary greatly, with survival ranging from a few months to more than ten years. Investigating data from 7,077 patients with newly diagnosed MM, we discovered that patients who are currently considered as 'intermediate-risk patients' constitute a quite diverse group with varying risk of progression or death. We identified a new prognostic system identifying 4 risk classes. With this model, about half of the patients can be classified as low or low-intermediate risk, and about half of them can be classified as intermediate-high or high risk. Oncologists can use our improved risk stratification model to better estimate patients' prognosis at the time of MM diagnosis. Moreover, this model favors the design of MM treatments tailored according to the individual risk of each patient."

Comprising data from 45,000 patients with blood cancers, makes the HARMONY Big Data Platform one of the largest of its kind in the world. HARMONY scientists use the Platform to characterize the molecular landscape of Hematologic Malignancies, understand their pathophysiology, and identify novel drug targets. Big data analytics has the potential to transform the treatment of patients with blood cancers. The ability to personalize the treatment of a patient based on molecular understanding of a disease or risk stratification will provide treatment strategies in the future to optimize outcomes for the patients.

More information

SOURCE HARMONY Alliance

https://www.harmony-alliance.eu

Original post:
New data from HARMONY demonstrate the power of Big Data analytics to inform personalized medicine in blood cancer - PRNewswire

News Release

Friday, December 4, 2020

Previously unknown genetic connection could be a target for gene therapy.

A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntingtons disease.

This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS.

Several neurological disorders have been linked to repeat expansions, a type of mutation that results in abnormal repetition of certain DNA building blocks. For example, Huntingtons disease occurs when a sequence of three DNA building blocks that make up the gene for a protein called huntingtin repeats many more times than normal. These repeats can be used to predict whether someone will develop the illness and even when their symptoms are likely to appear, because the more repeats in the gene, the earlier the onset of disease.

It has been recognized for some time that repeat expansion mutations can give rise to neurological disorders, said Sonja Scholz, M.D., Ph.D., investigator, NINDS Intramural Research Program. But screening for these mutations throughout the entire genome has traditionally been cost-prohibitive and technically challenging.

Taking advantage of technology available at NIH, the researchers screened the entire genomes from large cohorts of FTD/ALS patients and compared them to those of age-matched healthy individuals. While several patients had a well-established genetic marker for FTD/ALS, a small subset surprisingly had the same huntingtin mutation normally associated with Huntingtons disease. Remarkably, these individuals did not show the classical symptoms of Huntingtons but rather those of ALS or FTD.

None of these patients symptoms would have clued their physicians into thinking that the underlying genetic cause was related to the repeat expansion we see in Huntingtons disease, said Dr. Scholz.

She continued by explaining that whole genome sequencing is changing how neurological patients can be diagnosed. Traditionally, this has been based on which disease best fit the overall symptoms with treatment aimed at managing those symptoms as best as possible. Now, clinicians can generate genetically defined diagnoses for individual patients, and these do not always align with established symptom-based neurological conditions.

Our patients simply dont match a textbook definition of disease when it comes to which mutation produces which symptoms. Here we have patients carrying a pathogenic huntingtin mutation but who present with FTD or ALS symptoms, said Dr. Scholz.

One implication of these findings is that, if successful, these therapies could be applied to the small subset of FTD and ALS patients with that mutation as well. The researchers note that, while the number of FTD/ALS patients seen with the Huntingtons-linked mutation is small (roughly 0.12-0.14%), adding genetic screening for the mutation to the standard diagnostic procedure for patients showing symptoms of FTD or ALS should be considered.

Because gene therapy targeting this mutation is already in advanced clinical trials, our work offers real hope to the small number of FTD and ALS patients who carry this mutation, said Bryan Traynor, M.D., Ph.D., senior investigator, NIA Intramural Research Program. This type of large-scale international effort showcases the power of genomics in identifying the molecular causes of neurodegenerative diseases and paves the way for personalized medicine.

This research was supported by the Intramural Research Program of the National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke; project numbers 1ZIAAG000935, 1ZIANS003154, 1ZIANS003033, 1ZIANS003034), the Intramural Research Program of the National

NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIAs Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Dewan R. et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron. November 25, 2020. DOI:10.1016/j.neuron.2020.11.005

###

View original post here:
NIH researchers link cases of ALS and FTD to a mutation associated with Huntington's disease - National Institutes of Health

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST and will be conducted via live audio webcast at http://www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more opportunity for stockholders to vote on all proposals described in the Companys definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 3, 2020.

The record date for the Special Meeting remains October 28, 2020. Stockholders of record may vote at the reconvened Special Meeting, vote by proxy using the proxy card enclosed with the Companys definitive proxy statement, vote by proxy via facsimile, email or on the Internet. Whether or not stockholders of record plan to attend the reconvened Special Meeting, the Companys Board of Directors and management urge them to vote by proxy to ensure their vote is counted. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

A copy of the Companys proxy statement as previously filed with the SEC is available at no charge on the SEC website at http://www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Companys website at https://investors.predictive-oncology.com/ or by contacting the Companys Corporate Secretary at (651) 389-4806 or by mail to Corporate Secretary, Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, MN 55121.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IRJames Carbonara(646)-755-7412

See the original post:
Predictive Oncology Announces Adjournment of Special Meeting - GlobeNewswire

The cell therapy technologies market is expected to gain immense growth opportunities through the forecast period of 2019-2029 owing to the rising influence of cell therapies across the life sciences sector. The overwhelming need for novel and enhanced therapies for a variety of diseases and disorders may bring extensive growth prospects for the cell therapy technologies market during the forecast period.

The increased funding by the government may also prove to be a great growth prospect for the cell therapy technologies market. The precision medicine sector is evolving at a rapid rate across the globe. In this, a patient is given personalized treatment and is useful in making more accurate decisions. Thus, this factor may boost the growth of the cell therapy technologies market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6943

Cellular therapy is the transplantation of human cells to replace cells or tissues. This therapy can be used for treating various diseases and disorders. The evolution of cell therapy technologies is bringing immense advancements across the sector. This therapy is used mainly for nervous system disorders and cancer. The growing cases of these diseases may further invite promising growth.

On the basis of product, the cell therapy technologies market can be segmented into consumables, cell processing equipment, single-use equipment, other equipment, and systems and software. Based on cell type, the cell therapy technologies market can be classified into stem cells, T-cells, and other cells. Cell therapy technology is utilized expansively in biopharmaceutical and biotechnology companies and CROs, and research institutes and cell banks.

The enhancements in cell therapy technology research through immense investments from various sectors may invite prominent growth prospects for the cell therapy technologies market.

This report has extensive information on a plethora of aspects related to the growth of the cell therapy technologies market. The L.E.A.P mechanism applied by the researchers enables a 360-degree view of the cell therapy technologies market. The CXOs derive the perfect information that allows them to chalk out their business strategy accordingly. This report also has scrutinized information about the novel coronavirus outbreak and its effect on the cell therapy technologies market.

Cell Therapy Technologies Market: Competitive Insights

The cell therapy technologies market is highly fragmented. Numerous players are involved in intense competition for gaining a prominent position among the end-users. The players are also involved in expansion activities through mergers and acquisitions. Some well-entrenched players in the cell therapy technologies market are Danaher Corporation, CellGenix GmbH, IxCells Biotechnology, Wilson Wolf Corporation, SIRION Biotech GmbH, Dickinson and Company, and FUJIFILM Irvine Scientific.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6943&ltype=S

Cell Therapy Technologies Market: COVID-19 Impact

The COVID-19 impact may offer bright opportunities for the cell therapy technologies market to gain growth. The rising transmission of COVID-19 has led to rapid research and development activities in terms of an effective drug or vaccine. Cell-based research and technologies play an important role in the discovery of vaccines. Hence, this aspect may bring expansive growth prospects for the cell therapy technologies market.

Cell Therapy Technologies Market: Regional Prospects

The cell therapy technologies market in North America may gain a dominant position throughout the forecast period of 2019-2029. The maximizing research and development activities across the region for a good COVID-19 vaccine may bring profitable growth for the cell therapy technologies market. Robust healthcare expenditure, rising disposable income, and growing healthcare awareness may invite promising growth.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6943

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

See more here:
Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market - BioSpace

There may be nothing quite as gut-wrenching as sitting at the bedside of a loved one, watching helplessly as their life comes to an end. Perhaps the only thing more painful is when that loved one no longer recognizes you, slipping away not knowing who it was holding their hand.

November is deemed Alzheimers Awareness Month. Though with the degenerative brain disease now affecting roughly 5.8 million Americans and their families today, its perhaps not so much an increase of awareness thats needed, but rather a desperate need for effective treatment.

Alzheimers is the only disease among the top 10 causes of death in America that cannot be prevented, cured or even slowed. Over a decade and billions of dollars have been spent on research to find a cure for Alzheimers, yet none have thus far proved real clinical benefit. If the elusive cure for Alzheimers isnt found soon, scientists estimate that by 2050 someone in the United States will develop the disease every 33 seconds.

While these statistics paint a pretty bleak picture, Cynthia Lemere, Ph.D., Associate Professor of Neurology at Brigham and Womens Hospital and Harvard Medical School, assured BioSpace that hope is not lost. Despite the many failed drug trials, Lemere says the horizon is finally looking optimistic and expects to see multiple treatments approved within the next few years.

Any therapy developed at this point is going to be probably good for one subsection of that 5.8 million people with Alzheimers disease. And maybe not even that population, but maybe the population that doesnt yet have Alzheimers disease but has the changes going on in their brain of Alzheimers, so we know that theyre on the track, Lemere said.

While no real treatment is yet approved, diagnostic capabilities have grown exponentially. When Lemere first started in the neurology field, a true Alzheimers diagnosis couldnt be given until autopsy. The past decade has shown that the pathology of the disease starts in the brain roughly 20 years before clinical symptoms. PET scans can determine those on a trajectory to develop Alzheimers and with new biomarker testing working towards FDA approval, theyll be able to predict onset of clinical symptoms.

Knowing those who are most likely to develop this degenerative brain disease and when opens opportunities for clinical trials that are in the works. The majority of treatments being developed right now are targeting that window before cognitive decline. There are currently 2,050 interventional studies listed on clinicaltrials.gov around the world for the treatment of AD.

One buzzworthy drug in the news is Biogens aducanumab. Back in March 2019, Biogen stopped two Phase III trials for the antibody drug based on an interim futility analysis that indicated a lack of efficacy. But after a full collection of their data, Biogen found there was indeed efficacy in the higher dosage group who received over 10 doses.

This left them with two very different sets of trial results EMERGE with a positive reading and ENGAGE with a negative. Lemere believes the evidence in the EMERGE trial was strong enough to show positive clinical benefits. Despite much criticism and doubts surrounding aducanumab, Biogen took it to the FDA with hopes for approval and received a harsh vote from an independent advisory committee. No word yet from the FDA. Lemere predicts the FDA will call for another, large Phase III study to confirm the positive result at the higher dose for the full study. Lemere consults with Biogen for the companys Alzheimers education program and is not involved with their drug development programs.

The main breakthrough in the past year for pharmaceutical treatment of AD is that researchers finally know what the right target is - a toxic amyloid oligomer formation that is a key driver for the disease. Biogen isnt the only one targeting it with their drug candidates. Also in the race are Alzheon with ALZ-801, Eisais BAN2401 and Roches gantenerumab.

Unlike the intravenous antibody candidates from the other three, Alzheons ALZ-801 is an orally administered amyloid oligomer inhibitor. Alzheon recently dosed their first patients in a Phase II biomarker study in APOE4 carriers. Patients with an APOE4 gene are at a much higher risk for developing Alzheimers, particularly if you were passed two of the genes. In August, the National Institute of Aging awarded Alzheon an unprecedented $47 million grant to assist with a Phase III clinical trial of ALZ-801. The trial is slated to start at the beginning of next year with a timeline of 2-3 years to complete. This Phase III will be dosing younger people with Alzheimers pathology to test for primary prevention, intervening before clinical symptoms appear.

A Shanghai-based biotech is targeting AD in a completely different way. Instead of targeting amyloid in the brain, Green Valleys candidate is going after the gut. GV-971 is an oral capsule with its primary ingredient derived from seaweed to therapeutically harnesses the abnormal production of amino acids, infiltration of immune cells to the brain, and in turn neuroinflammation via remodeling the gut microbiota. Reactions to this approach range from excitement to cautious optimism to downright skepticism. Time should soon tell if theres something to this approach as Green Valley has now identified its first patient for its Phase III trial in the US with the initial dose coming soon.

Drug developers arent the only ones trying to stop the devastating progression of AD. A research team at MIT found that in Alzheimer's mouse models, the right brain waves can drive microglia, scavenger cells that remove damaged neurons and infections in the central nervous system, to consume the toxic amyloid protein deposits. More research is being done in this area to explore this as a potential option for treatment in humans to reduce amyloid deposits in the brain.

Lemere listed off multiple research projects in the works for Alzheimers prevention therapies to prevent free-radical formation and reduce oxidative stress in the brain, studies into the importance of vascular health and its impact on AD, the effects of diet and exercise, and more. One study found significant results in patients using aggressive blood pressure therapy. People that had lowered their blood pressure and kept it around 120, compared to the control group hovering around 140, showed a significant slowing of the rate of visible cognitive impairment.

The Alzheimers Association, of which Lemere is a member of the medical and scientific advisory group, is sponsoring a lifestyle intervention study in the U.S. called POINTER, that takes into account exercise, nutrition, social interactions, cognitive stimulation and management of comorbidities to protect cognitive function in healthy older adults who are at an increased risk of cognitive decline.

The big point is that probably none of these is going to work by itself, Lemere said.

Rather she sees a future in which a doctor who sees Alzheimers pathology brewing in a patient will recommend a multi-prong defense.

I think its going to be a combination of treatments. And its not going to be the same combination for each person, Lemere said. Its going to be dependent on whatever else is going on with them. Because Alzheimers rarely occurs by itself. There are usually other comorbidities. So ultimately, I think it will be more personalized medicine and combination therapy.

In 2020 alone, the National Institutes of Health is expected to spend $2.8 billion on Alzheimers research. Costing the U.S. $277 billion a year, its the most expensive disease in America. Annual cost of care is projected to increase to $1.1 trillion by 2050. While the financial burden is exorbitantly high, for family members and caregivers its the emotional cost that leaves the deepest scars.

Arkansas resident Linda Crafton knows firsthand the devastating effects Alzheimers has on a family.

To me, its worst disease known to mankind. I used to think the way I lost my dad, which was an instant death, was the hardest way to lose someone, Crafton said. I now know that was wrong. The hardest way to lose your parent is day by day, little by little, an inch at a time.

Craftons mother and five of her mothers seven siblings were victims of the aggressive disease. She said shes in a generation of cousins who now live in fear of the future, wondering which of them will be the first to show the signs, the first to receive their own diagnosis.

Time magazine writer Jeffrey Kluger said, Suffering is always hard to quantify especially when the pain is caused by as cruel a disease as Alzheimer's. Most illnesses attack the body; Alzheimer's destroys the mind and, in the process, annihilates the very self.

Though a cure for Alzheimers has frustrated scientists for years, theyre closer now than theyve ever been before.

According to the Alzheimers Association, a lack of volunteers for clinical trials is one of the greatest obstacles slowing the progress of potential new treatments. If you or someone you love is on a trajectory for the development of Alzheimers disease, the association offers a free TrialMatch service to connect volunteers with clinical trials to advance research.

Most read today on BioSpace:

More:
Potential for an Alzheimer's Treatment Appears to Be Closer Than Ever - BioSpace

Latest launched research document on Pharma Clinical Trial Digitization Market study of 350 Pages provides detailed analysis with presentable graphs, charts and tables. This report covers a detailed study of the Pharma Clinical Trial Digitization Market size, growth, and share, trends, consumption, segments, application and Forecast 2027. The Research Study presents a complete assessment of the Market and highlights future trend, growth factors & drivers, leaders opinions, facts, and primary validated market data. The research study provides estimates for Pharma Clinical Trial Digitization Forecast till 2027. Pharma Clinical Trial Digitization Report is a comprehensive business study on the current state of industry which analyses innovative strategies for business growth and describes important factors such as top manufacturers, production value, key regions, and growth rate.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market&AB

Pharma Clinical Trial Digitization Market is accelerating owing to the demand of personalized medicine. The enhancement in the digital pharma services to keep the track of medication through the various components namely individualized drug printing, drug impact monitoring, bioprinting and others are defining the potential future of the pharma clinical trial digitization market during the forecast period of 2020 to 2027.

This upgradation of healthcare IT infrastructure and technological assistance being provided on vast scale is driving the market growth at the rate of 5.70% annual for the mentioned seven years. This momentum will be maintained by rising practice of individualized drug printing.

Pharma Clinical Trial Digitization Market report covers strategic profiling of key players in the market, comprehensively analyzing their core competencies, and their strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions which are applicable for the businesses with which they can take better steps to improve their strategies to sell goods and services. Market research study presents actionable market insights which help create sustainable and money-spinning business strategies. An absolute way to forecast what future holds is to comprehend the trend today. Thus, with this Pharma Clinical Trial Digitization business report, more important aspects of the Pharma Clinical Trial Digitization industry can be focused.

Pharma Clinical Trial Digitization Market Scenario

According to Data Bridge Market Research the Pharma Clinical Trial Digitization market is attaining a significant growth in the developing economies during the forecast period of 2020-2027 due to factors such as introduction of medical robots in hospitals, improving quality life of people, rising popularity of technologically advanced surgical robots and increasing diagnosis of diseases will boost the growth of the market. Pharma Clinical Trial Digitization Market is becoming more competitive every year with surgical robots will expect to attain maximum share during the period of 2020-2027. The Data bridge market research new reports highlight the major growth factors and opportunities in the Pharma Clinical Trial Digitization Market.

To Get the Short-Term and Long-Term Impact of COVID-19 on thisMarket@https://www.databridgemarketresearch.com/request-covid-19/global-pharma-clinical-trial-digitization-market&Ab

List of Significant Vendors Operating in this market include:

Antidote Technologies, Inc.AparitoClinerion Ltd.CliniOps, Inc.ConsilxDeep 6 AIKoneksa Health Inc.Medidata SolutionsOraclePatientsLikeMeTrialbeeTriNetX, Inc.Veeva Systems.Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&ab

This Pharma Clinical Trial Digitization Market Research document takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company. It consists of most-detailed market segmentation, systematic analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. The market insights and analysis provided in this market research document are based upon SWOT analysis on which businesses can trust confidently. This Pharma Clinical Trial Digitization report is produced by chewing over several fragments of the present and upcoming market scenario.

Global Pharma Clinical Trial Digitization Market Segments & Geographic Analysis:

By Services (Drug Dose Adjustment, Drug Impact Monitoring, Medical Prescription System, Bioprinting, Preventive Therapy, Individualized Drug Printing)

By Application (Clinical Data Management, Trial Monitoring, Patient Recruitment and Enrollment)

By Themes (Digital Continuity Across Clinical Trial IT Systems, Patient-centric Remote and Virtual Trial Design, Direct-to-patient Home Services)

Pharma Clinical Trial Digitization Market-Geographical Segment

North America (Canada, United States & Mexico)Europe (Germany, the United Kingdom, BeNeLux, France, Russia & Italy)Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)South America (Argentina, Brazil, Peru, Colombia, Etc.)Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)Global Pharma Clinical Trial Digitization Market Scope and Market Size

Pharma clinical trial digitization market is segmented of the basis of services, application and themes. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.

Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.

The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Years considered for this report:o Historical Years: 2010-2019o Base Year: 2019o Estimated Year: 2020o Pharma Clinical Trial Digitization Market Forecast Period: 2020-2027

With tables and figures helping analyses worldwide Global Pharma Clinical Trial Digitization market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Pharma Clinical Trial Digitization Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition byCompany:Here, the competition in the Worldwide Pharma Clinical Trial Digitization Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Pharma Clinical Trial Digitization Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Pharma Clinical Trial Digitization Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Pharma Clinical Trial Digitization Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Pharma Clinical Trial Digitization Market.

Market Forecast:Here, the report offers a complete forecast of the global Pharma Clinical Trial Digitization Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read the rest here:
Pharma Clinical Trial Digitization Market Size, Share, Revenue, Demand and Forecasted Healthcare Industry with Upcoming Trends and Expectations by...

Our virtualMedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.

One vexing part of any conversation on precision medicine and breakthrough therapies that have been developed and are continuing to work their way through clinical trials for cancer to rare disease is how to address the practical challenge of their high price tags. Although there are several models to cover the cost of these therapies such as Cignas Embarc Benefit Protection program,what happens when someone changes insurers when they change their job? What is fair for patients and whats fair for companies? When do these conversations even start?

The panel, Reimbursement Models for Cell and Gene Therapies, will highlight some of the pros and cons of different models that are coming to market. Panelists include Laura Okpala, Director, Reimbursement Policy, Gilead Sciences, and Mark Trusheim, Strategic Director, NEWDIGS initiative at the MIT Center for Biomedical Innovation.

Heres a preview of some of the sessions. Click here to see the agenda.

Interoperability Progress Report

How far have we progressed with sharing patient medical records? Patient data is key in unlocking riddles of medical science but interoperability is necessary to facilitate this. What companies are making an impact on a regional and national scale? What milestones are on the horizon? What obstacles continue to vex further advancement? How can we make medical records more accessible to patients?

Moderator: Elise Reuter, Senior Reporter, MedCity NewsSpeakers:Kevin Chaney, Senior Program Manager, Office of the National Coordinator for Health ITIda Sim, M.D., Ph.D., Professor of Medicine, University of California, San FranciscoNiko Skievaski, Co-Founder and President, Redox

What It Takes To Build A Successful, Regional BioInnovation HubPhiladelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part ofVenture Cafe Philadelphia.

(sponsored by IBX)

Lisa Dalton, Chief People Officer,Spark TherapeuticsAudrey Greenberg, Executive Managing Director,The Discovery LabsTiffany Wilson, President & CEO,University City Science Center

Moderator:Michelle Histand, Director of Innovation, Independence Blue Cross

Register nowand be part of the conversation at INVEST Precision Medicine.

More here:
Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine - MedCity News

This article is part of an op-ed series on engineering fields that will change the world byRutgers School of Engineeringfaculty.

By Umer Hassan

Real-world innovations from submarines to self-driving cars come straight from imaginary worlds of science fiction. Think Star Treks handheld tricorder, a medical diagnostic device that made its first appearance in the original TV series. This sci-fi precursor is now changing the face of personalized medicine by taking the tricorder concept to the next level.

Today, diabetics can anticipate a biosensor able to monitor their glucose levels through perspiration. A biosensor implant could detect genetic mutations as they happen, while British researchers are developing a wearable biosensor that will collect data and assess the efficacy of rehabilitation equipment and exercise.

Other biosensors will be able to quickly and inexpensively detect costly and potentially fatal medical conditions such as sepsis and AIDS. Together with Rutgers University colleagues, clinical and industry partners, my lab has been working to solve these global health challenges with new tools that focus on a highly personalized approach to medicine. Since the COVID-19 pandemic began, we are also hoping to apply this technology to fight the coronavirus.

Sepsis the bodys life-threatening response to infection is not only deadly, it is the most expensive inpatient medical condition in the United States, with patients who develop sepsis often spending days in intensive care units at a cost of $10,000 a day or more. Recognizing that sepsis is responsible for as many as 6 million largely preventable deaths a year, the World Health Organization has identified the prevention, diagnosis and management of sepsis as a pressing global health priority.

By applying electrical and computer engineering skills to identify new biomarkers and devise machine-learning algorithms, or artificial intelligence systems, we hope to dramatically improve clinicians' abilities to diagnose, predict and ultimately manage sepsis. Simply reacting to diseases is no longer enough we need to predict them in order to treat patients in a much smarter way.

To this end, we are building an inexpensive medical device that even minimally trained health care providers can use to accurately diagnosis sepsis. This automated device would cost less than $10 a test and be simple to operate not only in resource-limited settings but anywhere where a rapidly confirmed diagnosis of sepsis is needed.

In sub-Saharan Africa, where only one person in eight is even tested for HIV, many of those infected go undetected until they develop severe complications from the disease. In the near future, cheap, disposable biosensors that are as easy and convenient to use as a home pregnancy test, will detect infections with people living with HIV/AIDS in underdeveloped sub-Saharan African nations. A secondary goal is to develop sensors able to monitor a patients response to the antiretroviral therapy they receive.

The positive health and economic impact of such sensors would be felt not only in underdeveloped nations, but also in the United States by reducing the cost of a single HIV test from hundreds of dollars to as little as $10.

A smartphone-based microscope setup, working with a Galaxy S9+ attached to a 3D printed platform will display an image of white blood cells.

My lab has also made the fight against COVID-19 a priority and a natural extension of our existing work. We are seeking to develop a sensor that could measure the ability of white blood cells to kill the virus in high-risk human patients. This could lead to new therapeutic interventions and could help develop a rapid, easy-to-use widespread stratification test.

In terms of predicting health outcomes and personalizing therapeutic approaches economically, we are also collaborating with Robert Wood Johnson Medical Hospital to do just that by combining sensor data and electronic medical records data.

Advancing personalized medicine and health monitoring is also a key concern of my Rutgers School of Engineering colleague, electrical and computer engineering associate professor Mehdi Javanmard. His lab has been developing a lab on a chip with the potential to monitor everything from health to germs to pollutants.

His teams innovative biosensor could be used in hand-held devices akin to that old Star Trek tricorder or wearable devices that measure biomarkers to track your health and exposure to harmful bacteria, viruses, and pollutants.

While a single biomarker is measured in home pregnancy tests, multiple biomarkers need to be tracked simultaneously to diagnose and manage complex health conditions such as heart disease, cancer, and inflammatory diseases. The lab on a chip is designed to meet that challenge. Additionally, within the next three to five years, a lab on a chip could quickly analyze a sample of what if any harmful bacteria are on a doorknob of a bathroom; test a salad for the presence of E. coli or Salmonella bacteria; or even quickly test for the flu.

In time, a future version of the smartphone will be the true tricorder of tomorrow. Smartphone-based health sensors will ultimately transform the smartphone into an intelligent, all-in-one monitoring and diagnostic device.

Umer Hassan, an assistant professor of electrical and computer engineering at Rutgers University School of Engineering, holds a joint appointment at Rutgers Global Health Institute.

Our journalism needs your support. Please subscribe today to NJ.com.

Heres how to submit an op-ed or Letter to the Editor. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

See original here:
Star Trek-inspired personalized medicine is on the horizon | Opinion - NJ.com

Ibex Medical Analytics, a company in artificial intelligence (AI)-based cancer diagnostics and Institut Curie, Frances leading cancer center, today announced a research partnership aimed at improving diagnosis of breast cancer with AI.

Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Analysis of breast tissue samples by a pathologist, typically using gross exam followed by examination under a microscope of tissue sections from biopsies or surgical specimens, remains the standard method of diagnosing and staging cancer. However, in recent years, an increase in cancer prevalence, coupled with a decline in the number of pathologists specialized in diagnosing cancer, has resulted in greater workloads and relatively long wait times for test results. Clearly, there is a growing need for automated solutions and decision support tools that can help pathologists diagnose cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.

This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner, and analyzed for cancer detection by Ibexs Galen Breast solution. Independently, multiple pathologists from Institut Curie will diagnose the slides, followed by blinded analysis of the AI-solutions performance. Galen Breast, the first AI solution used for detection of breast cancer in pathology, was developed utilizing state-of-the-art AI and machine learning techniques, and trained on hundreds of thousands of image samples. The solution is already deployed at the pathology institute of Maccabi Healthcare Services, Israels second largest HMO, where it is used as a second read application.

The importance of breast pathology is ever increasing, as new and more personalized treatments for breast cancer become available, many of which are based on precision medicine and require more tests and diagnosis by pathologists, said Dr. Anne Vincent-Salomon, Director of Pathology at Institut Curie and the principal investigator in the study. We believe that artificial intelligence can help us meet these challenges, and we are delighted to partner with Ibex, the leader in AI for cancer diagnosis in pathology. This collaboration will enable our pathologists to experience AI firsthand and evaluate its utility for diagnosing breast cancer.

We are excited to partner with Institut Curie, a global leader in research and treatment of breast cancer, for the first-ever blinded and independent evaluation of an AI-solution for breast cancer detection, said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics. Our Galen Prostate solution has demonstrated outstanding clinical outcomes and empowers pathologists worldwide to improve diagnostic accuracy and implement 100% quality control. We are continuing to expand our platform to new tissue types, focusing this time on breast biopsies, and are thrilled to work with Dr. Vincent-Salomon and her world-leading team on this important breast cancer study.

"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company, added Amaury Martin, PhD, Head of Technology Transfer and Industrial Partnerships Office at Institut Curie and Head of Carnot Curie Cancer. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine.

More:
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - Technology Networks

Metabolites, the small non-polymeric molecules, which are the intermediate or final products of metabolic reactions, have emerged as powerful tools for biomedical research and precision medicine.The term metabolome, introduced in 1998, represents the whole entity of metabolites within a cell, tissue or entire organism.1Since then, metabolomics has gained impressive traction, especially due to its relevance in systems biology or the holistic approach of deciphering the complexity of biological processes. Metabolomics fits perfectly in that concept, with its strategic position downstream of genomics and transcriptomics in the omics cascade and also tightly connected and influenced by the surrounding environmental factors. Often, the metabolome provides insights where genomic profiling fails to explain a given phenotype, and for this, the field is gaining appreciation from a plethora of pathology-related areas, including cancer, diabetes and cardiac disease.2From a technical point of view, metabolite profiling relies on the principles of analytical chemistry. The main methods are mass spectrometry (ms), applied in a targeted or untargeted manner, nuclear magnetic resonance (NMR) and stable isotope labeling for matabolomic flux analysis. Each of these methods has its pros and cons and the choice depends on the study's final goals. 3, 4The diverse nature of the metabolome continually challenges researchers and creates a colorful array of opinions on which is the most comprehensive and precise approach.

"That's kind of the way targeted metabolomics is. You're looking for certain molecules, but you're only looking under the lights. And if it turns out that this is where you've lost your keys, then it works extremely well." Patti says. Nevertheless, the scientist highly appreciates the significance of targeted metabolomics: "Targeted metabolomics is extremely useful in the clinical arena and other areas of biology," but also acknowledges the importance of identifying novel metabolites and making new discoveries. "The advantage of untargeted metabolomics is the potential for discovering molecules or metabolites that are altered in a particular disease state or physiological condition that are not expected."

Patti's lab leverages on identifying new metabolites using untargeted metabolomics and he is no stranger to the obstacles this approach offers and how it differs from the targeted analysis. "When you do untargeted metabolomics, you don't know what you're looking for. The metabolic spaces are pretty ambiguous, and we can't optimize methods in the classical way that you would do in a targeted experiment," he reflects.

Newgard has a clear vision for the future and the potential of his method: "Where I see us going is always to have that strong foundation of targeted and quantitatively reproducible and rigorous profiling, but then link it to what's happening in metabolic pathways, through the ability to do metabolic flux analysis.

Although somewhat divided into their approaches and tools, metabolomics researchers are unified by their vision for a metabolomics-based approach to personalized medicine in the future, and by the common challenges they encounter and recognize. Their collective efforts will undoubtedly pave the way for deciphering the code of metabolomics.References:

1. Oliver S. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16(9):373-378. doi:10.1016/S0167-7799(98)01214-1.

2. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25(1):43-56. doi:10.1016/j.cmet.2016.09.018.

3. Zamboni N, Saghatelian A, Patti GJ. Defining the Metabolome: Size, Flux, and Regulation. Mol Cell. 2015;58(4):699-706. doi:10.1016/j.molcel.2015.04.021.

4. McGarrah RW, Crown SB, Zhang G-F, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018;122(9):1238-1258. doi:10.1161/CIRCRESAHA.117.311002.

5. Kraus WE, Muoio DM, Stevens R, et al. Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis. Lusis AJ, ed. PLOS Genet. 2015;11(11):e1005553. doi:10.1371/journal.pgen.1005553.

6. Yao C-H, Wang L, Stancliffe E, et al. Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software. Anal Chem. 2020;92(2):1856-1864. doi:10.1021/acs.analchem.9b03811.

7.Huang X, Chen Y-J, Cho K, Nikolskiy I, Crawford PA, Patti GJ. X 13 CMS: Global Tracking of Isotopic Labels in Untargeted Metabolomics. Anal Chem. 2014;86(3):1632-1639. doi:10.1021/ac403384n.8. Lu D, Mulder H, Zhao P, et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci. 2002;99(5):2708-2713. doi:10.1073/pnas.052005699.

9. Warburg O, Wind F, Negelein E. The Metabolism Of Tumors in the body. J Gen Physiol. 1927;8(6):519-530. doi:10.1085/jgp.8.6.519.

Follow this link:
Diverse Opinions to Common Challenges in the Field of Metabolomics - Technology Networks

Costa Rica has the conditions to move towards the adoption of a personalized health care approach, despite some pending challenges in its objective of impacting the entire population.

A research report Personalized medicine in Latin America: Universalizing the promise of innovation, prepared by the Intelligence Unit of The Economist (EIU, for its acronym in English) indicated this and also highlighted that it is the Central American country with better social, political, economic and health conditions for its application.

To contribute to greater and better local coverage, the study recommends the construction of an initial frame of reference that includes issues of governance, awareness, and attitudes; infrastructure and financial management, where patients, the medical community, and health authorities understand the possibilities and challenges of personalized medicine in aspects such as patient and doctor education, improvements in digital and laboratory infrastructure, transition to advances in medicine, among others issues.

The study had the support of Roche Latin America and in addition to Costa Rica, it included Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay. The nine countries were categorized as level one, two, or three, based on their assessment of the basic elements necessary for the successful implementation of personalized medicine, and where they are in the process.

The report places Costa Rica, Argentina, Brazil, Colombia, and Uruguay at level one, countries that it considers ready to decide, as it has substantial elements of the reference framework, but with important gaps in terms of its evaluation.

The best-prepared

At this level, Costa Rica is the Central American country best prepared to decide whether to create a comprehensive approach encompassing its entire health system and not just separate initiatives, which allows accompanying each patient on their journey, from prevention to treatment, monitoring and identifying their needs.

Follow this link:
Costa Rica is the Only country to advance in Personalized Medicine - The Costa Rica News

LONDON--(BUSINESS WIRE)--The RNA and DNA extraction kit market is poised to grow by USD 731.27 million during 2020-2024, decelerating at a CAGR of almost 9% during the forecast period.

For a More Detailed Analysis, Get a Free Sample Report Delivered in a Minute

The report on the RNA and DNA extraction kit market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the increasing incidence of cancer.

The RNA and DNA extraction kit market analysis includes product and geography landscape. This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the RNA and DNA extraction kit market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The RNA and DNA extraction kit market covers the following areas:

RNA And DNA Extraction Kit Market Sizing

RNA And DNA Extraction Kit Market Forecast

RNA And DNA Extraction Kit Market Analysis

Develop Smart Strategies for Your Business: Get a Free Sample Report Now!

Companies Mentioned

Related Reports on Health Care Include:

Global DNA Sequencing Market - Global DNA sequencing market is segmented by solution (products and services) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Synthetic Biology Market - Global synthetic biology market is segmented by application (healthcare, industrial, food and agriculture, and others) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Global RNA and DNA Extraction Kit Market Growth Will Decelerate at a CAGR of Over 9%, 2020-2024 | However, Market Registers an Incremental Growth of $...

Today marks the start of RSNA 2020, the annual meeting of the Radiological Society of North America. I participated in my first RSNA 35 years ago and I am super excitedas I am every yearto reconnect with my radiology colleaguesand friendsand learnabout the latestmedical and scientific advances in our field. Of course, RSNA will be very different this year. Instead of traveling to Chicago to attend sessions and presentations, and wander the exhibits, Ill experience it all online. While I will miss the fun, excitement, and opportunities to connect that come with being there in person, I am amazed by what a rich and comprehensive conference the organizers of RSNA 2020 have put together using the advanced digital tools that we have at hand now.

It would be an understatement to say that this has been a year in which nearly everything is very different. From the tragic loss of life and rampant sickness to the economic disruption and the impact on our professions and our childrens education, so much of what we have been through because of COVID-19 has been extremely difficult. But the resilience of the response that so many people and institutions have shown in the face of all these challenges has been remarkable. And if it is possible to say there has been some good in all this, it would have to be the unprecedented transformation of the global healthcare ecosystem as hospitals, clinicians, and researchers have embraced a new generation of advanced digital health technologies that have helped them respond to the coronavirus crisis and laid the foundation for a more effective, affordable, and equitable future for healthcare.

As we move forward and the digital transformation of healthcare continues to accelerate, I see three significant trends that will influence the future of health and wellness.

One is the rapid emergence of virtual care through digital tools such as telehealth and remote monitoring that have made it safer and more convenient for patients to connect with their doctors during the pandemic, and that is empowering individuals to take charge of their health in entirely new ways. Virtual care has the capacity to personalize, accelerate, and augment treatment and prevention, saving time and money while improving outcomes. The ability to engage patients without requiring an in-person visit to a clinic will help ensure that they receive the right level of care and enable healthcare facilities to better manage the flow of patients into clinics and emergency rooms.

The second trend is the growing clarity of the promise of AI-driven precision medicine to serve as a major catalyst for improving health outcomes. As platforms for precision medicine and real-world evidence mature, well see exciting opportunities to improve treatment and prevention as we personalize patient care and transform how we diagnose infectious disease, cancer, and autoimmune disorders.

And, finally, where healthcare organizations have long been reluctant to move data offsite due to security, trust, and privacy concerns, we have seen a historic shift to the cloud over the last nine months. Now, driven by regulatory changes, the massive increase in medical data, and the critical need to access and analyze all that data by providers, payers, public health agencies, and researchers, its clear to everyone that moving to the cloud is both essential and hugely beneficial, both to providers and to patients.

As part of Microsofts ongoing commitment to help healthcare customers and partners continue to make progress toward recovery and build more resilient and effective systems of care, in late October we announced the general availability of Microsoft Cloud for Healthcare. This powerful industry-specific solution provides integrated capabilities for automated and efficient high-value workflows, and advanced data analysis functionally for structured and unstructured data so that healthcare organizations can truly transform information into insight and insight into action.

Built on the trusted capabilities of Microsoft 365, Microsoft Azure, Microsoft Dynamics 365, and Microsoft Power Platform, Microsoft Cloud for Healthcare is designed to enhance patient engagement to make it easier for patients to interact with caregivers, empower health team collaboration to facilitate more efficient and rich real-time communication and collaboration across the care continuum, and improve clinical and operational data insights with the ability of healthcare organizations to connect data from across their systems to predict risk and help improve patient care and operational efficiencies. Our robust partner ecosystem extends the power of Microsoft Cloud for Healthcare by building and extending advanced health solutions to meet the most demanding challenges in healthcare.

All of this makes it a particularly exciting time to be a radiologist. In many ways, our field has always been at the forefront of advances in the technologies that improve the movement, management, and analysis of large amounts of health data. This shouldnt really be a surprise, given that medical imaging accounts for nearly three-quarters of all health data, and analyzing 3D medical images can require up to 50 GB of bandwidth a day.

At Microsoft, streamlining the flow of health data, including medical imaging data, has been a significant focus of our work over the past few years. With the release of the Medical Imaging Server for DICOM (Digital Imaging and Communications in Medicine) in September, we offer developers powerful tools to ingest and persist medical imaging data in the cloud. Elevating interoperability, this is the first cloud technology to bring together DICOM data standard and FHIR (Fast Healthcare Interoperability Resources) which allows for persisting medical imaging metadata alongside other clinical data and sets the stage for multiple scenarios in research and diagnosis which may be too difficult or expensive to execute today.

Now, with Project InnerEye and the open-source InnerEye Deep Learning Toolkit, were making machine learning techniques available to developers, researchers, and partners that they can use to pioneer new approaches by training their own ML models, with the aim of augmenting clinician productivity, helping to improve patient outcomes, and refining our understanding of how medical imaging can be combined with other types of data to advance personalized medicine.

Learn more about our latest medical imaging offerings at the RSNA industry hour lunch and learn on December 3, 12:30 PM 1:30 PM Central Time.

Reimagining an industry that is as complex and touches as many lives as healthcare is a massive undertaking and at Microsoft, we have the privilege of working with amazing partners who stand at the forefront of innovation and progress in medical imaging technology.

Our partners are building transformative solutions to address some of the most difficult challenges in medical imaging. The amount of data generated by medical diagnostic imaging and connected devices is growing exponentially. Healthcare stakeholders, therefore, need effective ways of handling these data at scale.

This prompted Siemens Healthineers to build a dedicated cloud environment for Healthcare: The teamplay digital health platform. Through a certified gateway, the teamplay receiver, health data from connected medical devices can be aggregated. The teamplay cloud infrastructure is based on Azure, allowing secured processing of data within or outside a hospitals network.

GE Healthcares Centricity Universal Viewer Zero Footprint (ZFP) connects advanced diagnostic tools and system-wide image management platforms across the care continuum to help healthcare organizations improve diagnostic speed and confidence. ZFP users can now open Microsoft Teams with one click and share studies with other clinicians via the secure and compliant channels.1

SOPHiA GENETICS, the company pioneering the Data-Driven Medicine movementtrusted by over 1000 healthcare institutions in 85 countriesis highlighting their radiomics capabilities through the universal SOPHiA Platform for oncology and COVID CT imaging. Radiomics transforms standard medical imaging into mineable data assets that can be analyzed and combined with genomic data for improved decision support of precision medicine. SOPHiA Radiomics Solutions offer comprehensive workflows for multiple research and disease indication needs. SOPHiA multimodal platform is deployed on Microsoft Azure Cloud.

Microsoft and Sectra are partnering on cloud-based enterprise imaging and AI. In our joint RSNA webinar, Reap the benefits of enterprise imaging in the cloud with Microsoft & Sectra on December 3, we will introduce the brand new all-Azure and hybrid Microsoft Azure Stack offering as well as a demo of how Teams integration will help radiologists to cope in the new virtual world. We will hear Judy Bartlett from our joint customer John Muir share her experiences about moving from on-prem to running the Sectra Enterprise Imaging Solution as a Service on Azure.

With the imminent release of a new version of iConnect Enterprise Archive, IBM Watson Health will start to bring to market solutions that support a containerized deployment, in addition to VMWare, on both the IBM Cloud and Azure. The containerization of this portfolio is one of IBM Watson Healths key initiatives, starting with their VNA foundation and leveraging IBMs Red Hat OpenShift technology to ensure build once and deploy anywhere to be cloud native and agnostic.

With NVIDIA Clara Imaging, developers and researchers have the ability to accelerate data annotation, build domain-specialized AI models, and deploy intelligent imaging workflows with state-of-the-art pre-trained models and reference applications. Working closely with Azure, these innovators can jumpstart their development in the cloud and also address tough medical imaging challenges faster.During the current pandemic, our partnership is heavily accelerating progress Research in drug discovery (UC, Riverside; UCB Covid Moonshot) using GPUs on Azure for quantum mechanics model as well as using AI for SARS COVID-19 risk evaluation in Italy (Hospital San Raffaele, Milan). This partnership also enables the development and deployment of smart hospital solutions, running on NVIDIA Clara Guardian and Azure.

And finally,Flywheel is a cloud-scale informatics platform for biomedical research and collaboration. What is exciting about their differentiated work is the ability to securely leverage cloud at the edge with Microsoft Azure Stack Hub and transform these image analytics with Microsoft AI enabling tools and Flywheels depth in medical imaging data management and automated workflows.

Microsoft is the only cloud that extends to the edge from Microsoft Azure Edge Zone for 5G to Microsoft Azure Sphere for security. Were removing all barriers by covering all security and data sovereignty concerns in the cloud. With over 168,000 partners around the world, the network for innovation and collaboration runs deep. We cannot wait to see how together we will build solutions that transform healthcare around the world.

For more information on Microsoft Cloud for Healthcare, AI imaging tools, or to learn more about partnership visit the Microsoft virtual booth at RSNA or connect with us at our featured demo on November 29, 2:00 PM 2:30 PM Central Time.

[1] Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

Go here to see the original:
Medical imaging, AI, and the cloud: what's next? - Microsoft Industry Blogs - Microsoft

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cycling jersey market and it is poised to grow by USD 237.28 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Click & Get Free sample report in minutes

Impact of COVID-19

The COVID-19 pandemic continues to transform the growth of various industries. However, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. COVID-19 will have a low impact on the cycling jersey market. The market growth in 2020 is likely to increase compared to the market growth in 2019.

Frequently Asked Questions-

Related Reports on Consumer Discretionary Include:

Global Cycling Wear Market: The cycling wear market size has the potential to grow by USD 2.98 billion during 2020-2024, and the markets growth momentum will accelerate during the forecast period because of the steady increase in year-over-year growth. To get extensive research insights: Click and Get FREE Sample Report in Minutes!

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. ASSOS of Switzerland GmbH, adidas AG, FOX HEAD Inc., Giant Manufacturing Co. Ltd., Jaggad Pty Ltd., Pending System GmbH & Co. KG, Rapha Racing Ltd., Shimano Inc., Trek Bicycle Corp., and Troy Lee Designs Inc. are some of the major market participants. The growing need for fitness activities will offer immense growth opportunities. In a bid to help players strengthen their market foothold, this cycling jersey market forecast report provides a detailed analysis of the leading market vendors. The report also empowers industry honchos with information on the competitive landscape and insights into the different product offerings offered by various companies.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Cycling Jersey Market 2020-2024: Segmentation

Cycling Jersey Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41655

Cycling Jersey Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The cycling jersey market report covers the following areas:

This study identifies growing demand for personalized medicine as one of the prime reasons driving the cycling jersey market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cycling Jersey Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Distribution channel

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Cycling Jersey Market to grow by USD 237.28 million during 2020-2024, ASSOS of Switzerland GmbH and adidas AG Emerge as Key Contributors to Market...

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST and will be conducted via live audio webcast at http://www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more opportunity for stockholders to vote on all proposals described in the Companys definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 3, 2020.

The record date for the Special Meeting remains October 28, 2020. Stockholders of record may vote at the reconvened Special Meeting, vote by proxy using the proxy card enclosed with the Companys definitive proxy statement, vote by proxy via facsimile, email or on the Internet. Whether or not stockholders of record plan to attend the reconvened Special Meeting, the Companys Board of Directors and management urge them to vote by proxy to ensure their vote is counted. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

A copy of the Companys proxy statement as previously filed with the SEC is available at no charge on the SEC website at http://www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Companys website at https://investors.predictive-oncology.com/ or by contacting the Companys Corporate Secretary at (651) 389-4806 or by mail to Corporate Secretary, Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, MN 55121.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IRJames Carbonara(646)-755-7412

Excerpt from:
Predictive Oncology Announces Adjournment of Special MeetingScheduled to Reconvene on December 30, 2020 - BioSpace

Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer. Intravesical BCG therapy is widely-used for bladder cancer. However, tumor recurrence and progression are very common. Stratification based on germline polymorphisms may contribute to circumvent this clinical challenge. Autophagy pathway plays an important role in the nonspecific protective effects of BCG. Patients that carry C allele of rs3759601 in autophagy gene ATG2B showed increased risk of recurrence and progression in European population. We thus sought to analyze rs3759601 and its relevance in BCG response in Asian NMIBC patients.

Functional impact of rs3759601 ATG2B (p.Gln1383Glu) was analyzed by bioinformatics programs including NCBI Conserved Domain Search, Clustal Omega, Polyphen and SIFT. NMIBC patients who received intravesical BCG at multiple hospitals in Singapore from 1995 to 2016 were included. These patients were genotyped for rs3759601 using high resolution melt analysis. The rs3759601 polymorphism was studied in correlation with the bladder cancer recurrence rate and disease progression rate in our cohort. Statistical analysis was conducted using Kaplan-Meier plots and the Chi-squared analysis.

In total, 307 individules were included in the study including 161 NMIBC patients and 146 healthy controls, predominately Chinese. The rs3759601 genotype distributions in our NMIBC patients were (GG 72.1%; GC 27.9%; CC 0%), which were distinct from the Dutch report (GG 32.8%; GC 47.4% and CC 19.8%, Buffen K et al, 2014). Consistently, the C allele frequencies of rs3759601 are 0.171 in our controls and 0.177 in East Asians from 1,000 Genome, but 0.406 in Europeans from 1,000 Genome. In silico analysis suggested rs3759601 ATG2B (p.Gln1383Glu) alteration is unlikely to be functionally deleterious. Statistical analysis revealed no significant association between ATG2B rs3759601 C allele and risk of bladder cancer recurrence (P= 0.353, GC vs. GG: hazard ratio [HR]= 1.324), or cancer progression (P= 0.454, GC vs. GG: HR=0.658).

In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients.

Urologic oncology. 2020 Nov 26 [Epub ahead of print]

Zhijiang Zang, Yew Koon Lim, Yiong Huak Chan, Lata Raman, Kesavan Esuvaranathan, Edmund Chiong, Ratha Mahendran

Department of Urology, National University Hospital, National University Health System, Singapore. Electronic address: ., Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33250346

Read the original:
Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Ba... - UroToday

The Scientist's annual award recognizes exciting biomedical technologies that have the potential to generate the biggest impact on scientific research. Seven Bridges GRAF was selected by The Scientist's independent panel of expert judges for its potential to improve methods for analyzing next-generation sequencing data, helping researchers overcome the inherent flaws in the human genome linear reference sequence, and improving understandings of genetic diversity in understudied populations such as people of African, Asian, Hispanic and Middle Eastern descent.

"Seven Bridges is the first to offer this type of graph-based bioinformatics solution," said William Moss, CEO of Seven Bridges. "This recognition underscores the greater importance Seven Bridges GRAFTMbrings to the research community and its value in helping scientists develop new understandings of global population diversity. We hope that this research ultimately improves precision medicine across global populations."

The company's comprehensive graph-based bioinformatics solution is designed to greatly improve the analysis of non-European ethnicities; support large, more diverse population studies; enable research on underrepresented populations; and aid in the development of personalized references for more precise analysis. Seven Bridges GRAF enables:

"The COVID-19 pandemic birthed a shared scientific purpose and accelerated innovation in 2020," said The Scientist Editor-in-Chief Bob Grant. "The winners of this year's competition embody the spirit of togetherness and ingenuity marshaled by the research community in the face of this unprecedented challenge."

In addition to the honor from The Scientist, this year, Seven Bridges GRAF was selected as the top performer in the precisionFDA Truth Challenge for the major histocompatibility complex (MHC) region. The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region.

"The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region," said Dr. H. Serhat Tetikol, the GRAF Product Director at Seven Bridges. "From a computational perspective, the complexity of such genomic loci is only exacerbated when one takes into account the variation between different ancestries. This is where the current linear human genome reference clearly falls short, and where our GRAF technology can provide significant utility over traditional methods."

For more information about Seven Bridges GRAF, visit http://www.sevenbridges.com/graf/.

About Seven BridgesSeven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated data sets, and expert on-demand professional services. This holistic approach to bioinformatics is enabling researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and even turn a failing clinical trial around while also reducing computational workflow times and data storage costs. To learn more, visitsevenbridges.comor follow us onLinkedInandTwitter.

Contact: Eric Schubert +1 415 692 6799 [emailprotected]

SOURCE Seven Bridges

Home

Read the rest here:
Seven Bridges GRAF Named #3 on The Scientist's Top 10 Innovations List for 2020 - PRNewswire